Edition:
India

Aerie Pharmaceuticals Inc (AERI.OQ)

AERI.OQ on NASDAQ Stock Exchange Global Market

53.85USD
23 Feb 2018
Change (% chg)

$1.30 (+2.47%)
Prev Close
$52.55
Open
$52.80
Day's High
$53.85
Day's Low
$52.15
Volume
66,128
Avg. Vol
125,627
52-wk High
$66.55
52-wk Low
$38.15

Chart for

About

Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02%... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $1,913.33
Shares Outstanding(Mil.): 36.34
Dividend: --
Yield (%): --

Financials

BRIEF-Aerie Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* AERIE PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Aerie Pharmaceuticals Commences Public Offering Of $75 Million Of Common Stock

* AERIE PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

24 Jan 2018

BRIEF-Aerie Pharmaceuticals Appoints Julia Williams As Director Of Medical Affairs

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF JULIA WILLIAMS AS DIRECTOR OF MEDICAL AFFAIRS Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-Aerie Pharma Enters Controlled Equity Offering Sales Agreement With Cantor Fitzgerald

* AERIE PHARMA SAYS ON DEC 19, CO ENTERED INTO CONTROLLED EQUITY OFFERING(SM)SALES AGREEMENT WITH CANTOR FITZGERALD - SEC FILING

19 Dec 2017

Aerie's glaucoma treatment gets early FDA approval

Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

19 Dec 2017

UPDATE 2-Aerie's glaucoma treatment gets early FDA approval

Dec 18 Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration (FDA) approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

19 Dec 2017

Aerie's glaucoma treatment gets early FDA approval

Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its eyedrop, Rhopressa, as a treatment for glaucoma, two months ahead of the expected date.

19 Dec 2017

BRIEF-Aerie Pharmaceuticals Gets U.S. FDA Approval Of Glaucoma Drug

* AERIE PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF RHOPRESSA® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02% FOR THE LOWERING OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

19 Dec 2017

FDA approves Aerie's glaucoma treatment

Dec 18 Aerie Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration approved its treatment for glaucoma, Rhopressa.

19 Dec 2017

BRIEF-Aerie Pharmaceuticals Appoints Heather Johnson As Regional Sales Director For Northeast Region

* AERIE PHARMACEUTICALS ANNOUNCES APPOINTMENT OF HEATHER JOHNSON AS REGIONAL SALES DIRECTOR FOR THE NORTHEAST REGION Source text for Eikon: Further company coverage:

04 Dec 2017

Earnings vs. Estimates